On July 28, AKESO declined 3.04% in regular trading, trading at HK$95.75/share, with turnover of HK$183 million.

On the news front, the company announced on July 26 that it granted 3,603,500 share options to 167 grantees at an exercise price of HK$99.50 per share, alongside 1,648,500 restricted share units to 162 grantees under its equity incentive plans. The current stock price has fallen below the exercise price, amplifying short-term market sentiment around potential dilution. The stock had rallied nearly 6% on July 23 following positive OS data updates from its global Phase III HARMONi study for ivonescimab, but has since pulled back for three consecutive trading days.

Within the Biotechnology sector, the overall sector was broadly weak. Among individual stocks, LEADS BIOLABS-B down 4.22%, KEYMED BIO-B down 4.31%, BEIGENE down 1.65%, INNOVENT BIO down 1.12%, 3SBIO down 1.05%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)